新疆维吾尔自治区人民医院眼科,新疆 乌鲁木齐 830001
Published:25 July 2023,
Received:09 October 2022,
扫 描 看 全 文
克里木江·阿不拉 ,宋艳,麦迪娜·那毕江 等.腔内注射雷珠单抗联合Ex-press引流植入术治疗新生血管性青光眼的疗效[J].局解手术学杂志,2023,32(07):612-616.
Abula Kelimujiang,SONG Yan,Nabijiang Maidina,et al.Efficacy of intraluminal injection of lucentis combined with Ex-press drainage implantation in the treatment of neovascular glaucoma[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(07):612-616.
克里木江·阿不拉 ,宋艳,麦迪娜·那毕江 等.腔内注射雷珠单抗联合Ex-press引流植入术治疗新生血管性青光眼的疗效[J].局解手术学杂志,2023,32(07):612-616. DOI: 10.11659/jjssx.10E022016.
Abula Kelimujiang,SONG Yan,Nabijiang Maidina,et al.Efficacy of intraluminal injection of lucentis combined with Ex-press drainage implantation in the treatment of neovascular glaucoma[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2023,32(07):612-616. DOI: 10.11659/jjssx.10E022016.
目的
2
探讨腔内注射雷珠单抗联合Ex-press引流植入术治疗新生血管性青光眼(NVG)的疗效。
方法
2
选取2019年7月至2020年7月我院眼科收治的NVG患者100例(100眼)作为研究对象,按照随机数字表法将其分为对照组和观察组,每组50例(50眼)。对照组给予单纯Ex-press引流植入术,观察组给予腔内注射雷珠单抗联合Ex-press引流植入术。比较2组患者治疗前后眼压、视力水平及治疗有效率。采用ELISA法测定并比较2组患者血浆及房水中转化生长因子β1(TGF-β1)和血清及房水中血管内皮生长因子(VEGF)、白介素-6(IL-6)及促红细胞生成素(EPO)水平。记录2组患者不良反应的发生情况。
结果
2
2组患者治疗后4周、3个月的眼压均较治疗前降低(
P
<
0.05),且观察组眼压明显低于对照组(
P
<
0.05);观察组患者治疗后4周、3个月的视力改善优于对照组(
P
<
0.05)。观察组的治疗有效率明显高于对照组(
P
<
0.05)。2组患者治疗后4周血浆中TGF-β1水平,血清中VEGF、IL-6水平和房水中VEGF、IL-6、TGF-β1、EPO水平均明显降低(
P
<
0.05),且观察组降低更明显(
P
<
0.05)。2组患者不良反应发生率比较差异无统计学意义(
P
>
0.05)。
结论
2
腔内注射雷珠单抗联合Ex-press引流植入术治疗NVG可有效降低眼内压,改善患者视力,下调TGF-β1、EPO水平,进而提高患者治疗有效率。
Objective
2
To investigate the efficacy of intraluminal injection of lucentis combined with Ex-press drainage implantation in the treatment of neovascular glaucoma (NVG).
Methods
2
A total of 100 NVG patients (100 eyes) admitted to the department of ophthalmology of our hospital from July 2019 to July 2020 were selected as the research subjects. They were divided into the control group and the observation group according to the random number table method, with 50 cases (50 eyes) in each group. The control group was given simple Ex-press drainage implantation, while the observation group was given intraluminal injection of lucentis combined with Ex-press drainage implantation. The intraocular pressure, visual acuity and treatment efficiency before and after treatment of the patients in the two groups were compared. ELISA was used to measure and compare the levels of transforming growth factor β1 (TGF-β1) in plasma and aqueous humor and the levels of vascular endothelial growth factor (VEGF), interleukin-6 (IL-6) and erythropoietin (EPO) in serum and aqueous humor. The occurrence of adverse reactions of the patients in the two groups was recorded.
Results
2
The intraocular pressure 4 weeks and 3 months after treatment of the patients in the two groups decreased compared to before treatment (
P
<
0.05), and the intraocular pressure of the observation group was significantly lower than that of the control group (
P
<
0.05). The visual acuity 4 weeks and 3 months after treatment of the patients in the observation group was better than those in the control group (
P
<
0.05). The effective rate of treatment in the observation group was significantly higher than that in the control group (
P
<
0.05). The levels of TGF-β1 in plasma,the levels of VEGF, IL-6 in serum and the levels of VEGF, IL-6, TGF-β1, EPO in aqueous humor 4 weeks after treatment of the patients were significantly reduced in the two groups (
P
<
0.05), and the decrease in the observation group was more obvious (
P
<
0.05). There was no significant difference in the incidence of adverse reactions between the two groups (
P
>
0.05).
Conclusion
2
Intraluminal injection of lucentis combined with Ex-press drainage implantation in the treatment of NVG can effectively reduce the intraocular pressure, improve the visual acuity, down-regulate the levels of TGF-β and EPO, thus improving the treatment efficiency of patients.
新生血管性青光眼雷珠单抗Ex-press引流植入术TGF-β1EPO
neovascular glaucomalucentisEx-press drainage implantationTGF-β1EPO
Hwang H,Lee N.Effect of anti-vascular endothelial growth factor on the surgical outcome of neovascular glaucoma:an overview and meta-analysis[J].Medicine,2021,100(39):e27326.doi:10.1097/MD.000 0000000027326http://dx.doi.org/10.1097/MD.0000000000027326.
Cicinelli MV,Di Nicola M,Gigliotti CR,et al.Predictive factors of radio-induced complications in 194 eyes undergoing gamma knife radiosurgery for uveal melanoma[J].Acta Ophthalmol,2021,99(8):e1458-e1466.doi:10.1111/aos.14814http://dx.doi.org/10.1111/aos.14814.
黄宝辉.EX-PRESS青光眼引流器植入术联合超声乳化术治疗原发性急性闭角型青光眼合并白内障的临床疗效[J].广西医学,2020,42(16):2112-2115.doi:10.11675/j.issn.0253-4304.2020.16.14http://dx.doi.org/10.11675/j.issn.0253-4304.2020.16.14.
刘志英,崔巍.新型EX-PRESS青光眼引流器联合雷珠单抗治疗新生血管性青光眼[J].国际眼科杂志,2020,20(5):847-851.doi:10.3980/j.issn.1672-5123.2020.5.23http://dx.doi.org/10.3980/j.issn.1672-5123.2020.5.23.
毛丹娜.康柏西普和雷珠单抗治疗新生血管性青光眼的临床疗效对比[J].临床眼科杂志,2020,28(3):214-218.doi:10.3969/j.issn.1006-8422.2020.03.006http://dx.doi.org/10.3969/j.issn.1006-8422.2020.03.006.
吴小琴,郭 扬,高建兰.雷珠单抗注射联合Ex-PRESS引流器对新生血管性青光眼的疗效[J].国际眼科杂志,2016,16(2):300-302.
Feizi S,Alemzadeh-Ansari M,Karimian F,et al.Use of erythropoietin in ophthalmology:a review[J].Surv Ophthalmol,2021,67(2):427-439.doi:10.1016/j.survophthal.2021.06.002http://dx.doi.org/10.1016/j.survophthal.2021.06.002.
中华医学会眼科学分会青光眼学组.我国青光眼引流阀植入手术操作规范专家共识(2016年)[J].中华眼科杂志,2016,52(6):407-409.doi:10.3760/cma.j.issn.0412-4081.2016.06.003http://dx.doi.org/10.3760/cma.j.issn.0412-4081.2016.06.003.
王家凤,刘贺婷,陶黎明.屈光参差性弱视与斜视性弱视临床疗效的比较[J].国际眼科杂志,2022,22(2):211-214.doi:10.3980/j.issn.1672-5123.2022.2.07http://dx.doi.org/10.3980/j.issn.1672-5123.2022.2.07.
韩嵩.玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效及对患者血清CRP VEGF眼压和视力的影响[J].河北医学,2020,26(9):1478-1482.doi:10.3969/j.issn.1006-6233. 2020.09.017http://dx.doi.org/10.3969/j.issn.1006-6233.2020.09.017.
Choi W,Bae HW,Shin HJ,et al.Predicting the safety zone for steroid-induced ocular hypertension induced by intravitreal dexamethasone implantation[J].Br J Ophthalmol,2021,106(8):1150-1156.doi:10.1136/bjophthalmol-2020-318401http://dx.doi.org/10.1136/bjophthalmol-2020-318401.
赵媛,余敏,代艳,等.康柏西普联合EX-PRESS青光眼引流器植入对NVG患者视力及并发症的影响[J].国际眼科杂志,2020,20(10):1809-1813.doi:10.3980/j.issn.1672-5123. 2020.10.31http://dx.doi.org/10.3980/j.issn.1672-5123.2020.10.31.
陈帅征,穆雅林.雷珠单抗联合Ahmed青光眼引流阀植入治疗NVG的Meta分析[J].国际眼科杂志,2020,20(11):1931-1936.doi:10.3980/j.issn.1672-5123.2020.11.20http://dx.doi.org/10.3980/j.issn.1672-5123.2020.11.20.
杨玉春.雷珠单抗注射液联合改良小梁切除术治疗新生血管性青光眼的疗效及对血液流变学的影响[J].血栓与止血学,2020,26(3):441-443.doi:10.3969/j.issn.1009-6213.2020.03.030http://dx.doi.org/10.3969/j.issn.1009-6213.2020.03.030.
郑蓥蓥,张玉秋,王晓蕾,等.Ex-press青光眼引流钉植入术治疗不同类型青光眼的长期临床观察[J].中国眼耳鼻喉科杂志,2020,20(4):283-289.doi:10.14166/j.issn.1671-2420.2020.04.004http://dx.doi.org/10.14166/j.issn.1671-2420.2020.04.004.
Liu H,Ma Y,Xu HC,et al.Updates on the management of ocular vasculopathies with vegf inhibitor conbercept[J].Curr Eye Res,2020,45(12):1467-1476.doi:10.1080/02713683.2020.1781193http://dx.doi.org/10.1080/02713683.2020.1781193.
Watanabe-Kitamura F,Ogawa A,Fujimoto T,et al.Potential roles of the IL-6 family in conjunctival fibrosis[J].Exp Eye Res,2021,210:108708.doi:10.1016/j.exer.2021.108708http://dx.doi.org/10.1016/j.exer.2021.108708.
Garweg JG,Traine PG,Garweg RA,et al.Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen:a retrospective case series[J].Eye,2022,36(4):862-868.doi:10.1038/s41433-021-01562-6http://dx.doi.org/10.1038/s41433-021-01562-6.
Chen HY,Ho YJ,Chou HC,et al.TGF-β1 signaling protects retinal ganglion cells from oxidative stress via modulation of the HO-1/Nrf2 pathway[J].Chem Boil Interact,2020,331:109249.doi:10.1016/j.cbi.2020.109249http://dx.doi.org/10.1016/j.cbi.2020.109249.
孙 怡,邢怡桥,关文英. 红细胞生成素在新生血管性青光眼中的表达及体外血管诱导形成作用[J]. 中华医学杂志,2016,96(46):3729-3734.
0
Views
2
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
